Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Withdrawn before enrolling · Phase 2
Conditions studied: Colorectal Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with metastatic or recurrent colorectal cancer.
Key facts
- Study ID
- NCT00003786
- Run by
- University of Chicago
- People needed
- 0
- Starts
- 1999-04-01
- Expected to finish
- 2000-11-01
- Last updated by the study team
- 2014-03-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois at Chicago — Chicago, Illinois, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
- Lutheran General Cancer Care Center — Park Ridge, Illinois, United States
- Illinois Oncology Research Association — Peoria, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
- James Graham Brown Cancer Center — Louisville, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.